Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Open to people ages 18 years and up

• Histological or cytological diagnosis of SCCHN, RCC (clear cell and papillary cell), ovarian, gastric, esophageal (adeno and squamous), lung squamous cell, pancreatic and biliary duct, endometrial, melanoma, or urothelial cancer.

Part 2:

• Arm A SCCHN:
  • Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx.
  • PDL-1 expression positive and CPS ≥1. No prior systemic therapy administered in the recurrent or metastatic setting (except for systemic therapy given as part of a multimodal treatment for locally advanced disease).
• Arm B RCC (clear cell):
  • 1 or 2 prior lines of therapy including PD-L1/PD-1 immunotherapy in combination or sequentially with antiangiogenic directed treatment
• Adequate bone marrow, kidney and liver function.
• Performance status of 0 or 1.

• Participant disease status is suitable for local therapy administered with curative intent.
• Hypertension that cannot be controlled by medications.
• Active or prior autoimmune disease
• Active, uncontrolled bacterial, fungal, or viral infection, including (but not limited to) Hepatitis B, Hepatitis C, and known Human Immunodeficiency Virus infection or Acquired Immunodeficiency Syndrome-related illness